ASX:CYP - Cynata Therapeutics Stock Price, News, & Analysis

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.

Cynata Therapeutics (ASX:CYP) Frequently Asked Questions

What is Cynata Therapeutics' stock symbol?

Cynata Therapeutics trades on the ASX under the ticker symbol "CYP."

Has Cynata Therapeutics been receiving favorable news coverage?

News stories about CYP stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cynata Therapeutics earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Cynata Therapeutics.

Who are some of Cynata Therapeutics' key competitors?

Some companies that are related to Cynata Therapeutics include Neptune Wellness Solutions (NEPT), Biotest (BIO), Kodiak Sciences (KOD), BELLUS Health (BLU), Emerald Health Therapeutics (EMH), Monash IVF Group (MVF), Senesco Technologies (ELOX), Rafael (RFL), IMV (IMV), Emblem (EMC), Paradigm Biopharmaceuticals (PAR), 22nd Century Group (XXII), Horizon Discovery Group (HZD), Pfenex (PFNX) and OncoCyte (OCX).

What other stocks do shareholders of Cynata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cynata Therapeutics investors own include Starpharma (SPL), Mesoblast (MSB) and Immutep (IMM).

Who are Cynata Therapeutics' key executives?

Cynata Therapeutics' management team includes the folowing people:

• Dr. Ross Alexander MacDonald Ph.D., MD, CEO & Exec. Director (Age 61)
• Mr. Peter G. Webse B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. & Non-Exec. Director (Age 56)
• Dr. Kilian Kelly, VP of Product Devel.

What is Cynata Therapeutics' stock price today?

One share of CYP stock can currently be purchased for approximately A$1.25.

How big of a company is Cynata Therapeutics?

Cynata Therapeutics has a market capitalization of $126.85 million and generates $1.36 million in revenue each year. View Additional Information About Cynata Therapeutics.

What is Cynata Therapeutics' official website?

The official website for Cynata Therapeutics is http://www.cynata.com/.

How can I contact Cynata Therapeutics?

The company can be reached via phone at 61 3 9824 5254.